Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00051103 | Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin. | PHASE2 | COMPLETED | - | — | — | Oct 1, 2002 | Jun 1, 2005 | Apr 15, 2015 | 30 | United States |
| Name | Type | Description |
|---|---|---|
| Investigational Cancer Drug | DRUG | - |
Inclusion Criteria: (The patient must meet the following criteria in order to be eligible for this study.) * Signed informed consent * No more than two prior regimens for metastatic breast cancer. Each regimen must have contained Herceptin. * Refractory Stage IIIb or IV breast cancer * HER2/neu tum...